Home Journals Articles Updates About
CN
image
收藏切换
Advances in the study of new BCR-ABL kinase inhibitors
收藏切换
PDF
Wen-yu CUI, Ruo-xi ZHAO, Lu-lu HAN, Wei-wei NI, Fei LI*, Jin-song HAN*
Acta Pharmaceutica Sinica | 2023, 58(2) : 258 - 273
Less
收藏切换
Acta Pharmaceutica Sinica | 2023, 58(2): 258-273
• Reviews •
Advances in the study of new BCR-ABL kinase inhibitors
Full
Wen-yu CUI, Ruo-xi ZHAO, Lu-lu HAN, Wei-wei NI, Fei LI*, Jin-song HAN*
Affiliations
  • State Key Laboratory of Natural Medicines and National R & D Center for Chinese Herbal Medicine Processing, Department of Food Quality and Safety, College of Engineering, China Pharmaceutical University, Nanjing 211109, China
Published: 2023-02-12 doi: 10.16438/j.0513-4870.2022-0807
Outline
收藏切换

The oncogenic product of BCR-ABL is an abnormal tyrosine kinase that causes chronic myeloid leukemia (CML). With further research into the pathogenesis of CML, the discovery of compounds that selectively inhibit abnormal BCR-ABL tyrosine kinases is a research focus worthy of attention. The first three generations of BCR-ABL inhibitors are orthosteric inhibitors, which competitively block the binding of ABL protein tyrosine kinase to ATP and prevent it from activating downstream signals. The fourth-generation BCR-ABL inhibitors allosterically inhibit ABL protein tyrosine kinase by binding to the myristoyl pocket, providing greater selectivity and maintaining activity against drug-resistant mutations proteins. Novel drug design strategies such as proteolytic targeting chimera (PROTAC), covalent inhibitors and dual targeting inhibitors also provide new directions for the development of BCR-ABL kinase inhibitors. This paper reviews recent research advances on BCR-ABL kinase inhibitors and discusses drug design strategies for various novel BCR-ABL inhibitors.

chronic myeloid leukemia  /  BCR-ABL  /  inhibitor  /  drug design strategy
Wen-yu CUI, Ruo-xi ZHAO, Lu-lu HAN, Wei-wei NI, Fei LI, Jin-song HAN. Advances in the study of new BCR-ABL kinase inhibitors[J]. Acta Pharmaceutica Sinica, 2023 , 58 (2) : 258 -273 . DOI: 10.16438/j.0513-4870.2022-0807
Appendix
Less
Year 2023 volume 58 Issue 2
PDF
203
89
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2022-0807
  • Receive Date：2022-07-04
  • Online Date：2025-11-21
  • Published：2023-02-12
Article Data
Affiliations
History
  • Received：2022-07-04
  • Revised：2022-08-25
Funding
Affiliations
    State Key Laboratory of Natural Medicines and National R & D Center for Chinese Herbal Medicine Processing, Department of Food Quality and Safety, College of Engineering, China Pharmaceutical University, Nanjing 211109, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2022-0807
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House